Nazacort AQ nasal spray 120 doses

Trade name:

Nazacort AQ

Nasacort AQ

Composition and form of release:

Nasal spray 120 doses.

The active ingredient is Triamcinolone acetonide 55 μg / dose.

Pharmachologic effect:

The drug belongs to the group of intranasal glucocorticosteroids.

It has anti-inflammatory, anti-allergic, anti-edema effect. Reduces bronchial hyperreactivity.

In therapeutic doses, it practically does not have a systemic effect, does not suppress the function of the adrenal cortex; does not cause sodium retention in the body and the appearance of edema.

The onset of action is after 12 hours, reaching a maximum on 4-7 days of therapy.

Indications:

Seasonal and perennial allergic rhinitis (prevention and treatment), accompanied by symptoms such as congestion, itching, sneezing and nasal flow. The drug has an effect only when used as a course and is not indicated for immediate relief of symptoms.

Contraindications:

Hypersensitivity, childhood (up to 6 years), pregnancy, lactation.

With care: Tuberculosis, acute fungal, bacterial and viral infections, herpetic lesions of the eyes.

Side effects:

Headache, sneezing, cough, dry nasal mucosa, nasal irritation, nosebleeds, pharyngitis, rhinitis, fungal infection of the nose and throat caused by Candida albicans. Children aged 6-12 years – sinusitis, otitis media, vomiting.

Special instructions:

Intranasal administration in patients with nasal septal ulcers, nasal trauma or after nasal surgery may delay wound healing.

In case of development of candidiasis of the mucous membranes of the nose or pharynx, the drug should be discontinued and appropriate therapy should be prescribed.

Do not use for more than 3 months in children under 12 years of age to avoid systemic effects.

Dosing regimen:

Intranasal, adults and children over 12 years of age: 220 mcg / day (2 inhalation doses in each nasal passage), once; if necessary, the dosage can be increased to a maximum of 440 mcg / day (applied, once, or divided into 2-4 doses).

Children aged 6-12 years: 110 mcg / day (1 inhalation dose in each nasal passage), once. The maximum daily dose is 220 mcg.

After achieving a therapeutic effect in a number of patients, it is possible to reduce the daily dose to the minimum maintenance dose – 110 μg / day; dose reduction is carried out gradually, decreasing it by 55 mcg / day (1 inhalation dose), every 4-7 days.